ABIVAX is an innovative biotechnology company targeting the immune system to eliminate viral diseases using its unique antiviral technology platform.
ABIVAX leverages three technology platforms for drug discovery:
- an antiviral platform
- an immune enhancement platform
- a polyclonal antibody platform
ABX464, its most advanced compound, is currently in Phase 2 clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS. It is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (e.g. Respiratory Syncytial Virus (RSV), Influenza and Dengue), and several of these compounds are planned to enter clinical development within the next 18 months.
5, rue de la Baume